Published in Disease Risk Factor Week, February 19th, 2006
"Despite the fact that TRAIL can selectively induce apoptosis in cancer cells, TRAIL resistance in cancer cells has challenged the use of TRAIL as a therapeutic agent. First, prostate carcinoma cell lines (DU145, LNCaP and PC3) were screened for sensitivity to adenovirus delivery of TRAIL (Ad5hTRAIL)," wrote A.D. Sanlioglu and colleagues, Akdeniz University.
"As amplified Ikappa B kinase (IKK) activity is responsible for the constitutive nuclear...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Disease Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.